NASDAQ:NMRA Neumora Therapeutics Q2 2026 Earnings Results & Report $0.36 -0.01 (-1.67%) As of 09:57 AM Eastern This is a fair market value price provided by Massive. Learn more. Neumora Therapeutics beat analyst earnings expectations in its Q2 2026 results, released August 14, 2026. The company reported EPS of -$0.23 versus the -$0.2401 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 14, 2026TimeBefore Market OpensConference Call7:00 AM ET Neumora Therapeutics EPS ResultsActual EPS-$0.23Consensus EPS -$0.2401Beat/MissBeat by +$0.0101One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersNeumora Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsNeumora Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Neumora Therapeutics Q2 2026 Earnings FAQ Did Neumora Therapeutics beat earnings estimates for Q2 2026? Neumora Therapeutics (NASDAQ:NMRA) reported earnings of -$0.23 per share for Q2 2026, beating the consensus estimate of -$0.2401. The report was announced on Friday, August 14, 2026. When is Neumora Therapeutics' next earnings date? Neumora Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Neumora Therapeutics on the company's earnings history page. Neumora Therapeutics Earnings HeadlinesNeumora Therapeutics (NASDAQ:NMRA) Stock Dropped to "Strong Sell" by Wall Street ZenOctober 10, 2026 | americanbankingnews.comNeumora Therapeutics, Inc. (NMRA)September 15, 2026 | finance.yahoo.comWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock ahead of October 20. His system has spotted at least seven of the top 10 performers every year since 2016, including all ten in the 2022 bear market and every member of the Magnificent Seven before their run higher. Now Chaikin's Power Gauge is turning bullish on an under-the-radar company tied to next-generation AI data centers built under Executive Order 14363, technology he says uses 99 percent less electricity and space while offering far greater computing power.October 14 at 1:00 AM | Chaikin Analytics (Ad)Top Neumora Executive Makes Notable Move With Insider Stock SaleAugust 21, 2026 | tipranks.comNeumora Therapeutics Announces CEO Transition and Q2 ResultsAugust 14, 2026 | tipranks.comNeumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | globenewswire.comSee More Neumora Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Neumora Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neumora Therapeutics and other key companies, straight to your email. Email Address About Neumora TherapeuticsNeumora Therapeutics (NASDAQ:NMRA) is a clinical-stage biopharmaceutical company focused on developing treatments for disorders of the brain. The company combines neuroscience research with data science, including its proprietary MAP platform, to identify patient subgroups, discover potential drug targets and support the development of therapies for neurological and neuropsychiatric conditions. Neumora’s lead investigational product is navacaprant, an oral, selective kappa opioid receptor antagonist being evaluated for major depressive disorder. The company is also advancing additional programs aimed at conditions such as schizophrenia and other brain disorders. These products remain investigational and have not been approved for commercial use unless authorized by applicable regulatory agencies. Neumora was founded in 2019 through a collaboration involving ARCH Venture Partners and Amgen and is headquartered in Watertown, Massachusetts. The company became publicly traded on the Nasdaq under the symbol NMRA in 2023. Its operations and clinical development activities are primarily focused on the United States and international clinical-trial markets.View Neumora Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
